Sign in Create account
Sign in and upgrade to a paid plan to export price history as CSV.

Coral Laboratories Ltd.

Healthcare · Pharmaceuticals & Biotechnology

BSE: 524506
₹568.05
▲ 23.05 (4.23%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
63/100
Moderate
Valuation
99/100
Undervalued
Momentum
32/100
Neutral

QVM read Cheap on its own multiples Quality Moderate, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹203 Cr
PE (TTM)
10.6
Industry median 36.1 (152 companies)
Price to Book
1.0
PEG (TTM)
-0.5
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-28.1
Free Cash Flow
₹-5 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
110.03%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-19.61%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-8.51%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
110.14%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
57.39%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
6.48
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.02
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
182.92
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
18.19%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
23.54%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
27.39%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
6.81%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
10.92%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
7.83%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 7 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.02)
  • No Return on equity is 15% or more (7.8%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

2 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
4.2%
Low 545.2000 · High 572.0000
1W return
-5.0%
Low 534.6500 · High 594.8000
1M return
-8.7%
Low 534.6500 · High 639.0000
52W return
-28.1%
Low 534.6500 · High 679.0000
Lifetime High ₹1134.2000 (May 10, 2017)
Lifetime Low ₹24.6000 (March 20, 2009)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish4
Bearish2
5D
562.0
10D
567.5
20D
577.3
50D
578.6
100D
545.5
200D
470.6

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
100.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

561.75
Pivot
First resistance578.30
Second resistance588.55
Third resistance605.10
First support551.50
Second support534.95
Third support524.70
Day RSI46.2
Day MFI59.3
Day MACD-11.80
Day MACD signal-10.50

Beta

1M0.97
3M0.14
1Y0.14
3Y0.80

Price change analysis

↓ -8.7%
Over 1 Month
LowHigh
534.65639.00
↓ -28.1%
Over 3 Months
LowHigh
534.65679.00
↓ -28.1%
Over 6 Months
LowHigh
534.65679.00
↓ -28.1%
Over 1 Year
LowHigh
534.65679.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 10.6 (own history: 8.4–17.2)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹30 Cr
Net profit (June 30, 2026)
₹5 Cr
Basic EPS (June 30, 2026)
₹15.0800

Ranks #118 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter71.51%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 71.51% in Jun 2026 qtr

Historical fii holding

Historical mutual fund holding

All shareholding details →

Deals (Bulk & Block)

All 91 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
24 May 2024 NEELAM MITTAL Bulk Sell 1,100 539.6200 BSE
24 May 2024 NEELAM MITTAL Bulk Buy 21,709 537.8200 BSE
8 Sep 2022 VAIBHAV RAJENDRA DOSHI Bulk Sell 19,050 276.4800 BSE
13 Dec 2021 GUTTIKONDA VARA LAKSHMI Bulk Sell 20,000 286.8900 BSE
20 Apr 2020 GUTTIKONDA VARA LAKSHMI Bulk Buy 20,000 164.9500 BSE
22 Apr 2014 SHAILESH OMPRAKASH JALAN Bulk Sell 23,667 90.0000 BSE
25 Sep 2012 NAVIN BACHUBHAI DOSHI Bulk Buy 34,570 67.0800 BSE
21 Sep 2012 NAVIN BACHUBHAI DOSHI Bulk Buy 27,440 68.0000 BSE
18 Sep 2012 NAVIN BACHUBHAI DOSHI Bulk Buy 34,980 66.0000 BSE
17 Sep 2012 CHETAN DOSHI Bulk Buy 30,000 69.3300 BSE

All bulk and block deals →

Dividends

Full dividend history →
Ex-dateSubjectPer share (₹)Record date
— Final Dividend - Rs. - 2.0000 — —

Corporate Announcements

All 8 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
30 Sep 2026 AGM/EGM Coral Laboratories Ltd - 524506 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
29 Sep 2026 AGM/EGM Coral Laboratories Ltd - 524506 - Shareholder Meeting / Postal Ballot-Outcome of AGM
25 Sep 2026 Insider Trading / SAST Coral Laboratories Ltd - 524506 - Closure of Trading Window
25 Sep 2026 Board Meeting Coral Laboratories Ltd - 524506 - Board Meeting Outcome for Considered And Approved Cost Audit Report In CRA-3 For The Financial Year 2025-26
21 Sep 2026 Board Meeting Coral Laboratories Ltd - 524506 - Board Meeting Intimation for Intimation Of Board Meeting Scheduled To Be Held On September 25, 2026
5 Sep 2026 Company Update Coral Laboratories Ltd - 524506 - Announcement under Regulation 30 (LODR)-Newspaper Publication
4 Sep 2026 AGM/EGM Coral Laboratories Ltd - 524506 - Notice Of 44Th AGM Scheduled To Be Held On September 29, 2026
4 Sep 2026 Others Coral Laboratories Ltd - 524506 - Reg. 34 (1) Annual Report.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.02)
  • Comfortable interest coverage (182.9x)
  • Strong revenue growth YoY (57.4%)

Weaknesses

  • Low Return on Equity (7.8%)

Opportunities

  • PE below 15 (10.6) relative to a typical growth business
  • Trading below book value (PB 0.97)

Threats

  • Down 28.1% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Coral Laboratories Ltd.

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.